HAEMONETICS CORP — Director's Dealing 2013

Apr 5, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2013-04-03

Reporting Person: CONCANNON BRIAN (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-04-03	Common Stock	D	488.0	$41.83	Disposed	115798	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Qualified Stock Option (right to buy)	$11.3175	2013-09-15	Common Stock (50000)	50000	Direct
Non-Qualified Stock Option (right to buy)	$13.0525	2014-05-05	Common Stock (30000)	30000	Direct
Non-Qualified Stock Option (right to buy)	$25.535	2014-10-24	Common Stock (45780)	45780	Direct
Non-Qualified Stock Option (right to buy)	$26.47	2016-10-27	Common Stock (159350)	159350	Direct
Non-Qualified Stock Option (right to buy)	$27.275	2015-10-22	Common Stock (57176)	57176	Direct
Non-Qualified Stock Option (right to buy)	$27.495	2017-10-27	Common Stock (236750)	236750	Direct
Non-Qualified Stock Option (right to buy)	$27.685	2016-04-02	Common Stock (65690)	65690	Direct
Non-Qualified Stock Option (right to buy)	$30.67	2018-10-25	Common Stock (219572)	219572	Direct
Non-Qualified Stock Option (right to buy)	$39.055	2019-10-24	Common Stock (250382)	250382	Direct

Footnotes

F1: Pursuant to a 10b5-1 Plan.

F2: Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.

F3: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.